title: [Evaluation of body weight in patients with Graves' disease during the treatment with methimazole].
abstract: OBJECTIVE
  To evaluate weight change during hyperthyroidism treatment, and to correlate it with IL-6 and TNF-alpha concentrations.
  
  
  METHODS
  Forty two patients were included. Body weight (BW), body mass index (BMI), clinical and laboratory characteristics were recorded. IL-6 and TNF-alpha were determined before treatment with methimazole (MMI) and in euthyroidism.
  
  
  RESULTS
  BW was 59.62 ± 11.5 kg in hyperthyroidism, and 69.91 ± 14.4 kg in euthyroidism (p < 0.001). BMI increased from 23.1 ± 3.8 kg/m(2) to 27 kg/m(2) ± 4.7 during treatment (p < 0.0001). Before treatment, 66.6% subjects had BMI < 25 kg/m(2) and 33.3%, BMI > 25 kg/m(2). In euthyroidism, 38% of patients had BMI < 25 kg/m(2) and 62%, BMI > 25 kg/m(2) (p = 0.01). In euthyroidism, we found a significant reduction in IL-6 and TNF-alpha concentrations, but no correlation between IL-6 and TNF-alpha, and BW or BMI.
  
  
  CONCLUSIONS
  An important increase in BW and BMI was observed during hyperthyroidism treatment, and IL-6 and TNF-alpha alterations were only related with return to euthyroidism.
authors.affiliation: Instituto de Assistência Médica ao Servidor Público do Estado de São Paulo (IAMSPE), São Paulo, SP, Brasil. rlmoretto@yahoo.com.br
authors.forename: Renata Loureiro
authors.initials: RL
authors.lastname: Moretto
authors.forename: Ana Beatriz P
authors.initials: AB
authors.lastname: Pedro
authors.forename: Alex Carvalho
authors.initials: AC
authors.lastname: Leite
authors.forename: João Hamilton
authors.initials: JH
authors.lastname: Romaldini
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006111:Graves Disease / Q000150:complications; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000209:etiology; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D013961:Thyroid Gland / Q000502:physiology; D013963:Thyroid Hormones / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D015430:Weight Gain
chemical_list: D013956:Antithyroid Agents; D015850:Interleukin-6; D013963:Thyroid Hormones; D014409:Tumor Necrosis Factor-alpha; D008713:Methimazole